Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update
To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 1470397. A live webcast of the presentation will be available on the Investors & Media section of the Editas Medicine website.About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com. Contacts:
Investors
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.comMedia
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com